Kura Oncology (NASDAQ:KURA – Get Free Report) and Exicure (NASDAQ:XCUR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.
Risk & Volatility
Kura Oncology has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Exicure has a beta of 3.63, meaning that its stock price is 263% more volatile than the S&P 500.
Profitability
This table compares Kura Oncology and Exicure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kura Oncology | -384.30% | -207.18% | -45.17% |
| Exicure | N/A | -237.91% | -61.98% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kura Oncology | $67.48 million | 14.19 | -$278.67 million | ($3.37) | -3.19 |
| Exicure | $500,000.00 | 15.85 | -$4.95 million | ($1.32) | -0.92 |
Exicure has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and price targets for Kura Oncology and Exicure, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kura Oncology | 1 | 1 | 10 | 0 | 2.75 |
| Exicure | 1 | 0 | 0 | 0 | 1.00 |
Kura Oncology currently has a consensus price target of $25.40, suggesting a potential upside of 136.06%. Given Kura Oncology’s stronger consensus rating and higher probable upside, equities analysts plainly believe Kura Oncology is more favorable than Exicure.
Insider & Institutional Ownership
42.8% of Exicure shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Exicure beats Kura Oncology on 8 of the 14 factors compared between the two stocks.
About Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
About Exicure
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
